Shanghai Yaogu Pharmaceutical

Yaogu Pharma is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on the discovery and development of innovative small molecule drugs for oncology. The company leverages a proprietary drug discovery platform that integrates covalent chemistry and allosteric regulation to target proteins previously considered undruggable. Its lead clinical candidate, YG-001, is a potent and selective SHP2 inhibitor currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors. In addition to its SHP2 program, Yaogu Pharma is advancing a pipeline of inhibitors targeting the RAS signaling pathway, including KRAS and SOS1. The company aims to provide transformative therapies for cancer patients by addressing unmet medical needs through precise molecular engineering.